Effects of refractory status to lenalidomide on safety and efficacy of selinexor, bortezomib, and dexamethasone (XVd) versus bortezomib and dexamethasone (Vd) in patients with previously treated multiple myeloma.

Authors: Xavier Leleu Mateos, Maria-Victoria Jagannath, Sundar and Delimpasi, Sosana Simonova, Maryana Spicka, Ivan Pour, Ludek and Kriachok, Iryna Gavriatopoulou, Maria Dimopoulos, Meletios A. Pylypenko, Halyna Auner, Holger W. Reuben, Benjamin and Venner, Christopher P. Garg, Mamta DeCastro, Andrew Shah, Jatin J. Grosicki, Sebastian Richardson, Paul G.
Publication date: 1 January 2021
Publisher

Abstract

Abstract is not available.

Similar works

Full text

thumbnail-image

Available Versions

Pergamos : Unified Institutional Repository / Digital Library Platform of the National and Kapodistrian University of Athens

redirect

oai

oai:lib.uoa.gr:uoadl:3196685

Last time updated on 10/02/2023